Mohamad H Zanjanian, MD | |
930 Clifton Avenue, Clifton, NJ 07013-2723 | |
(973) 471-9191 | |
(973) 470-9858 |
Full Name | Mohamad H Zanjanian |
---|---|
Gender | Male |
Speciality | Allergy & Immunology |
Location | 930 Clifton Avenue, Clifton, New Jersey |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1144264508 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207K00000X | Allergy & Immunology | 27180 (New Jersey) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mohamad H Zanjanian, MD 930 Clifton Avenue, Clifton, NJ 07013-2723 Ph: (973) 471-9191 | Mohamad H Zanjanian, MD 930 Clifton Avenue, Clifton, NJ 07013-2723 Ph: (973) 471-9191 |
News Archive
Imagine reaching to pet your cat, and it hisses at you. How does your brain take stock of the sound and communicate with your body to pull back your hand?
In patients with type 2 diabetes and acute coronary syndrome, the glucose-lowering medication lixisenatide did not increase or decrease the rate of cardiovascular (CV) events compared to placebo, according to results of the Evaluation of Lixisenatide in Acute Coronary Syndrome (ELIXA) trial.
The Asian American Diabetes Initiative (AADI) at Joslin Diabetes Center has received a $70,089 grant from Tufts Health Plan Foundation to fund Healthy Living for All Seasons, which offers elderly Asians with, or at risk for, diabetes the opportunity to take part in educational workshops and seminars focusing on exercise, improved diet, and the prevention of diabetes complications.
Lantis Laser Inc., announced today that it has signed a Letter of Intent to merge with Perio-Imaging Inc., a private New York based company. The merger would be an all stock transaction and closing, among other conditions, would be subject to raising the required funding to complete the proposed merged company's product development program. The name of the new merged company will be announced upon closing.
Patients on peritoneal dialysis (PD) typically have a higher early survival rate than patients on hemodialysis (HD). New data suggest that this difference may be explained by a higher risk of early deaths among patients undergoing HD with central venous catheters, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
› Verified 4 days ago